.png){kind=logo}
Ketamine is a catalyst for growth.
When used in a safe environment with the right support, ketamine can provide important benefits.
Improved emotional regulation
Better attention and decision-making
Increased ability to evolve behavior patterns
Safe
Ketamine is traditionally used as an anesthetic. It is a World Health Organization "Essential Medicine" and favored as an anesthetic given its strong safety profile. Research indicates low dependency risk.
We conduct a thorough medical screening for all potential clients to screen for particular risk factors.
All treatments are administered by licensed medical professionals
Legal
Ketamine is the only psychedelic substance available for clinical use in the United States. It is used as an off-label treatment for treatment-resistant mental health conditions.
We perform thorough medical intakes for all interested to clients to determine treatment eligibility.
Ketamine prescription and administration is performed in the treatment jurisdiction.
Therapeautic
Ketamine has been shown to be an effective catalyst for alleviating symptoms associated with anxiety, depression, addiction, PTSD and chronic pain.
A recent study demonstrates:
89%
of ketamine recipients report improvements in mental health related symptoms
63%
of ketamine recipients experience a >50% reduction in symptoms
Ketamine supports outcomes with direct benefits to the nervous system.
.png)
At lower doses, ketamine stimulates the production of the excitatory neurotransmitter glutamate.
Glutamate increases the production of chemicals related to neural upkeep and growth.
Neural growth supports the regeneration of synaptic activity, providing relief from mental health symptoms and improving the ability to clear old behavior patterns.
The ketamine treatment experience is unique to every individual and demonstrates common themes.
A licensed medical professional administers ketamine via sublingual lozenge or intramuscular injection; effects typically last from 45-90min.
Emotion
Access to a heightened sense of emotional experience, including previously unconscious feelings
Body
New and amplified experiences of sensation in the body that call attention to somatic understanding
Mind
Novel experience of mind or conscious experience that provide new perspectives and ideas
Clients can add ketamine treatment to any program.
Psychedelics are a tool in the transformation process. We ensure all clients prepare for and integrate the psychedelic treatment experience with support from licensed professionals.
Indicate interest
Medical intake
Preparation
Treatment
Integration
Indicate your interest in using ketamine to support your program
Conduct a medical intake with a prescribing physician who will determine treatment eligibility
Prepare for the treatment experience with professional support in line with your defined program
Ketamine treatment administered in-person by a licensed medical professional
Support translating treatment insights into practical applications to support new ways of being
Frequently Asked Questions
How do I know if I qualify for ketamine treatment?
Ketamine is a controlled substance available only for the treatment of relevant conditions. Ketamine also has important "contraindications," or situations which rule it out as suitable treatment option. We help individuals understand if they qualify and any related risks during our intake process.
What if not all team members qualify or do not feel comfortable with ketamine treatment?
We accommodate individuals who will not receive the ketamine treatment but wish to participate in the overall healing journey by altering programming to fit their needs.
Will our team be comfortable doing the treatment together?
Sensitive issues can surface during treatment. However, we ensure the group sets a collective intention and boundaries before starting treatment to improve participants' comfort. Adopting the vulnerability required to participate in the program is a vital component of the healing process and provides additional healing benefits.
Where is Levity based?
Levity is registered in New Mexico, USA, and operates in a mobile fashion. We conduct all preparation and integration work virtually and travel to meet your team in their preferred treatment location. This can be anywhere from your office, to a local studio or clinic or even an outdoor venue. Prices vary to reflect the level of investment in the location.
What if I would like to participate with a group but don't have one?
If you're interested in experiencing the power of a group-based psychedelic-assisted therapy program, but don't have a company, professional organization or other team with which to apply, you can contact us to see if we can pair you with an appropriate group.
Is ketamine addictive?
Research suggests that developing reliance on ketamine is unlikely; preliminary research outcomes suggest that ketamine may even help treat addiction. However, given ketamine is a ‘mind-altering’ substance, there can still be a risk of developing dependency; we will discuss this and any related concerns during client intake consultations.
Can ketamine cause psychosis?
Research shows that psychosis as a result of psychedelic administration is extremely unlikely, especially when administered in a controlled environment. However, given the ability to cause disorientation, individuals prone to psychosis should not use psychedelic treatments. Our intake consultation will screen for particular risks.
Psychedelic science and care is growing.
Ongoing research is clarifying the impacts and healing mechanisms of ketamine and other psychedelic compounds. Relevant journal articles and research centers provide additional information.
A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression
Ketamine, an N-methyl-D-aspartate glutamate receptor antagonist, has demonstrated a rapid-onset antidepressant effect in patients with treatment-resistant depression.
Antidepressant efficacy of ketamine in treatment-resistant major depression:
a two-site randomized controlled trial
Shows ketamine displays rapid antidepressant effects and NDMA receptor modulation as a novel mechanism for chronic depression.
Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression
Finds no serious drug-related adverse events or increased ketamine craving or abuse post-administration after single dose.
Ketamine treatment for depression:
opportunities for clinical innovation and ethical foresight
Concludes ketamine for treatment-resistant depression is in line with ethical principles and clinicians must ensure to follow good practices.
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial
Shows evidence of rapid reduction in symptom severity following ketamine infusion in patients with chronic PTSD and depression with no persistent dissociative symptoms.
In 2000, the research group at the Center for Psychedelic & Consciousness Research was the first to be awarded regulatory approval to reinitiate psychedelic research after a nearly 30-year federal research ban. Their seminal work focuses on the impact of psychedelics on behavior, mood, cognition, brain function and biological health markers.
The Center for Psychedelic Research is part of the NYU Langone’s Department of Psychiatry. Researchers conduct and support high-quality, health-focused research to realize the clinical potential of psychedelic compounds and related drugs.
The Centre of Psychedelic Research focuses on the use of psychedelics for the treatment of mental health conditions and as a means of exploring the basis of consciousness. The Centre also aims to become a prototype for the licensed psychedelic care facilities of the future.
MAPS is a non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics. The organization is largely responsible for the progress of MDMA through FDA clinical trials.
Further research
Several additional universities are undertaking psychedelic research projects outside of formal psychedelic research centers. These include, but are not limited to:
Harvard University
Yale University
Stanford University
Northwestern University
University of Chicago
Columbia University
University of Michigan
University of Wisconsin, Madison
Emory University
University of California, Berkley
University of California, Los Angeles